Antinuclear antibodies and cancer: A literature review

Vlagea, Alexandru; Falagan, Sandra; Gutiérrez-Gutiérrez, Gerardo; Moreno-Rubio, Juan; Merino, María J.; Zambrana, Francisco; Casado, Enrique; Sereno, María

doi:10.1016/j.critrevonc.2018.05.002

Cited by 66 publications

(68 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…16 Despite the literature concerning the risk of cancer in SSc, the role of some autoantibodies in the risk of cancer among SScpatients is still controversial with conflicting findings in relationship to key SSc-linked autoantibodies including anti-Scl-70. 17 Moreover, there is a dearth of knowledge on the outcome of SScpatients and with respect to their autoantibody status and cancer. Also, the impact of different cancer subtypes on the mortality of SSc-patients has not been defined.…”

Section: Introductionmentioning

confidence: 99%

Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival

et al. 2019

View full text Add to dashboard Cite

Background: A higher rate of cancer in systemic sclerosis (SSc) is recognized but the role of SSc-linked autoantibodies status (positive/negative and autoantibody specificities) in the survival of SSc-patients with cancer remains poorly understood. Methods: We utilized the Clalit-Health-Services medical database in a case-control study to evaluate the autoantibody status and specificities of SSc-patients with age-and sex-matched controls with regard to the prevalence of different cancer-subtypes and their impact on mortality. SSc-linked autoantibodies (ANA, anti-centromere, anti-RNP, anti-RNA polymerase III (RNAPIII) and anti-Scl-70) status was assessed in terms of cancer risk and outcome. Results: 2,431 SSc-patients and 12,377 age-and sex-matched controls were included. SSc-patients had a relative risk of cancer of 1.90 (95%CI 1.62-2.24, p < 0.0001) and tended to develop malignancies earlier than controls. RNAPIII and Scl-70 autoantibody were associated with an increased overall cancer risk and after SSc diagnosis risk of cancer, respectively. As expected, SSc-patients with cancer had a risk of death of 2.15 (1.65-2.79) in comparison to SSc-patients without cancer. ANA-positive SSc-patients with cancer had a better prognosis than ANA-negative cases (p = 0.0001). Despite the benefit of ANA-positive status on survival, the anti-Scl-70-positive subgroup with cancer had a significant negative impact on the survival compared to Scl-70-positive cases without cancer, whereas anti-RNAPIII and anti-centromere had no significant impact. Conclusion: ANA positivity is an independent predictor of favorable prognosis in SSc-patients with cancer, possibly suggesting that humoral autoimmunity in SSc with cancer may have some benefit. However, no survival benefit was discernible with the common autoantibodies.

show abstract

Section: Introductionmentioning

confidence: 99%

Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival

et al. 2019

View full text Add to dashboard Cite

show abstract

“…On the contrary, cancer formation is caused by compromised host's immune system that cannot recognize cancer antigens. It has been previously reported that the immunogenicity of cancer cell could induce the production of a wide range of auto-antibodies including ANA, anti-dsDNA, anti-Sm, anti-SSA, anti-SSB, anti-Rib and anti-nRNP [27]. The level of ANA has been reported to be elevated in 31.5% lymphoma patients relative to the control group [12].…”

Section: Discussionmentioning

confidence: 98%

The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study

Guo

Ren

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Systemic lupus erythematosus (SLE) is associated with increased risk of cancer and the mechanism remains unclear. Here, we examined the level of auto-antibodies and disease activity index scores in SLE patients with cancers, and analyzed whether medications for SLE management might contribute to the higher cancer risk in SLE patients. Methods: In this retrospective study, we carried out a nested case-control study in a large cohort of SLE patients. We screened 5858 SLE patients to identify the newly diagnosed and yet to be treated cancers. The following clinical features were evaluated: auto-antibodies levels, SLE disease activity index scores and previous medication used for SLE management. Systemic glucocorticoid, cyclophosphamide, hydroxychloroquine (HCQ), methotrexate and azathioprine were considered the main medication indices. Results: Our analyses identified 51 SLE patients who also had cancer, and 204 matched control patients who had SLE but not cancer. Of the 51 SLE patients, thyroid cancer (14/51, 27.45%), cervical cancer (10/51, 19.61%) and lung cancer (7/51, 13.73%) were the most common types. Our analyses did not reveal any significant differences in the levels of auto-antibodies in SLE patients with cancers relative to the control group. Further, we observed that disease activity was significantly lower in SLE patients with cancers relative to the matched control SLE group. There was no statistically significant association between the cancer risk and the use of systemic glucocorticoid, cyclophosphamide, methotrexate or azathioprine. Importantly, the administration of HCQ was significantly lower in SLE patients suffering cancers relative to the cancer free matched control group. Conclusions: Our analyses indicate that SLE patients with cancers might have a lower disease activity at the time of cancer diagnosis. HCQ was negatively associated with cancer risk in SLE patients. These findings highlight a potential and novel prevention strategy for SLE.

show abstract

“…Pozitivna antinuklearna antitijela mogu se naći i u pacijenata s različitim vrstama karcinoma. Podaci govore da mogu biti uključena u patogenezu karcinoma i premalignih stanja 16 . Kod pacijentice nije dokazana bolest vezivnoga tkiva, međutim, slikovne obrade kojim su dokazane cistične promjene jajnika te limfadenopatija uz značajno povišenu vrijednost LDH-a zahtijevale su dodatne obrade (MR i PET/CT), koje su dovele do dijagnoze seroznog karcinoma visokog gradusa.…”

Section: Uvodunclassified

Raynaud’s phenomenom as a first manifestation of high grade serosus carcinoma

Turina

Eminović

Ferari

et al. 2019

Med. Flum. (Online)

View full text Add to dashboard Cite

Sažetak. Cilj: Prikazati slučaj pacijentice s Raynaudovim fenomenom kao prvom manifestacijom seroznog karcinoma visokog gradusa te dijagnostički i terapijski postupak. Prikaz slučaja: Pacijentica stara 47 godina upućena je na Odjel za reumatologiju i kliničku imunologiju zbog pozitivnih antinuklearnih antitijela i Raynaudova fenomena. Kliničkim pregledom i laboratorijskom obradom isključena je sistemska bolest vezivnog tkiva. Ultrazvukom abdomena uočena je cistična tvorba u području zdjelice. Tumorski markeri CA-125, HE-4 bili su povišeni. PET/CT analizom (pozitronska emisijska tomografija / kompjutorizirana tomografija) uočeno je pojačano nakupljanje radiofarmaka u supra/ retroklavikularnim limfnim čvorovima, zdjelično i paraaortalno. Citološka punkcija limfnog čvora na vratu upućivala je na metastatski slabodiferencirani adenokarcinom. Učinjena je laparoskopija desnog i lijevog jajnika, obostrana salpingektomija te zdjelična limfadenektomija. Patohistološka analiza potvrdila je da se radi o intraepitelnom seroznom karcinomu visokog gradusa jajovoda. Nakon dijagnostičke obrade provedeno je 6 ciklusa kemoterapije (Paklitaksel i Carboplatina). Na kontrolnom CT-u nije bilo znakova diseminacije osnovne bolesti. Pacijentica je trenutno dobrog općeg stanja i liječi se Olaparibom. Raynaudov fenomen je u značajnom poboljšanju. Zaključak: Serozni karcinom visokog gradusa može se prezentirati na atipičan način. Iznenadna pojava Raynaudova fenomena kod mlađih osoba treba pobuditi sumnju na moguću malignu bolest. Ključne riječi: karcinom jajnika; karcinom jajovoda; Raynaudov fenomen; serozni karcinom visokog gradusa Abstract. Aim: To present a case of a patient with Raynaud's phenomenom as the first manifestation of a high grade serosus carcinoma. Case report: A 47-year-old female has been referred to the Department of Rheumatology and Clinical Immunology due to the positive antinuclear antibodies and Raynaud's phenomena. Both clinical examination and laboratory treatment excluded systemic connective tissue disease. Abdominal ultrasound revealed cystic formation in the pelvis area. Tumor markers CA-125, HE-4 were elevated. PET / CT analysis (positron emission tomography/computed tomography) observed increased radiotracer uptake involving supra/retroclavicular lymph nodes, pelvic and paraortal. The cytology of the lymph node at the neck indicated a metastatic weak-bound adenocarcinoma. Left and right ovarian laparoscopy, double salpingectomy and pelvic lymphadenectomy were performed. The pathological analysis confirmed that it was intraepithelial serous high grade

show abstract

Antinuclear antibodies and cancer: A literature review

Cited by 66 publications

References 60 publications

Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival

Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival

The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study

Raynaud’s phenomenom as a first manifestation of high grade serosus carcinoma

Contact Info

Product

Resources

About